NCT00867100View on ClinicalTrials.gov

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Psoriasis
Interventions
DRUG

700 mg IV

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

DRUG

350 mg SC

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

DRUG

Placebo

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

DRUG

140 mg SC

single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00867100 - Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827 | Biotech Hunter | Biotech Hunter